neuroClues closes €10M Series A led by EIC Fund for digital biomarkers in neurology — EIC strategic validation
Summary
neuroClues closed a €10 million Series A round in April 2026 led by Teampact.ventures, White Fund SA, and the EIC Fund (European Innovation Council's investment arm), as reported in Neurotech Notables #52. The company develops digital biomarker tools for neurological disease monitoring and drug development. The EIC Fund's participation is strategically significant — the EIC invests specifically in deep tech companies addressing European strategic priorities, and neuroClues' digital neurology biomarker platform was identified as qualifying for direct EIC equity investment alongside the Teampact and White Fund venture investors.
Why it matters
EIC Fund co-investment in a neurological digital biomarker company is a European strategic technology designation — the EIC fund invests public European capital in companies developing technologies the EU considers strategically important. For neuroClues, EIC backing provides both capital and the implicit endorsement of European neurology digital health infrastructure as a strategic priority, which will help with subsequent clinical partnerships across EU member state health systems.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial